Renate Winkels

Wageningen University & Research
Country flagNetherlands
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Background Liver fat accumulation has been associated with impaired colorectal cancer prognosis. Associations may differ for colon and rectal cancer due to different disease mechanisms and dissemination patterns. Here, we investigated associations between liver fat and cancer recurrence, recurrence-free survival (RFS), and overall survival (OS) among 1596 individuals with stage I-III colon or rectal cancer. Methods Within a prospective cohort study, we used data from adults recently diagnosed with colon (n = 1080) or rectal (n = 516) cancer. Liver fat was evaluated using routine contrast-enhanced computed tomography (CT)-scans taken at diagnosis. Cox proportional hazards regression analyses adjusted for clinical and lifestyle-related variables were used to obtain hazard ratios (HRs) and 95% confidence intervals (95% CIs). Results During a median follow-up of 6.4 and 8.8 years, 247 (15%) recurrences (12% for colon and 22% for rectal cancer) and 418 (26%) deaths (25% for colon and 29% for rectal cancer) occurred, respectively. More liver fat was associated with an increased recurrence risk (HRT3vsT1 = 1.60, 95% CI = 1.02 to 2.50), worse RFS (HRT3vsT1 = 1.45, 95% CI = 1.05 to 2.00), and OS (HRT3vsT1 = 1.67, 95% CI = 1.20 to 2.33) among individuals with colon cancer. Liver fat was not associated with recurrence (HRT3vsT1 = 0.70, 95% CI = 0.42 to 1.18), RFS (HRT3vsT1 = 0.87, 95% CI = 0.59 to 1.30), or OS (HRT3vsT1 = 1.15, 95% CI = 0.74 to 1.80) among individuals with rectal cancer. Conclusion More liver fat was associated with poor clinical outcomes in patients with stage I-III colon cancer. Further studies are needed to confirm these findings and explore mechanistic routes linking liver fat to colon cancer prognosis.

Year:

2025

Sensitivity analyses on the association between hematocrit levels and severity of CRF at the different timepoints among survivors that were fatigued or anemic at least once during the study period

Year:

2024

Sensitivity analyses on the association between hematocrit levels and severity of CRF at the different timepoints among survivors that were fatigued or anemic at least once during the study period

Year:

2024

Background: Cancer-related fatigue (CRF) is a frequent symptom in colorectal cancer survivors. It is unknown to what extent anemia may contribute to CRF in colorectal cancer survivors. This study aimed to investigate the association between hematocrit, as marker for anemia, and CRF among colorectal cancer survivors from diagnosis until two years thereafter. Methods: The study population included 1,506 newly diagnosed colorectal cancer survivors at any stage of disease from a prospective cohort study. Hematocrit and CRF (EORTC QLQ-C30) were assessed at diagnosis, six months, and two years after diagnosis. Multivariable logistic regression or multivariable linear mixed models were used to assess the associations of hematocrit with CRF prevalence, or CRF severity over time, respectively. Results: A low hematocrit (levels Conclusions: Lower hematocrit levels were longitudinally associated with a higher prevalence and severity of CRF in colorectal cancer. Impact: Our findings emphasize the importance of long-term anemia monitoring and a potential role of anemia in CRF among colorectal cancer survivors.

Year:

2024

Background: Cancer-related fatigue (CRF) is a frequent symptom in colorectal cancer survivors. It is unknown to what extent anemia may contribute to CRF in colorectal cancer survivors. This study aimed to investigate the association between hematocrit, as marker for anemia, and CRF among colorectal cancer survivors from diagnosis until two years thereafter. Methods: The study population included 1,506 newly diagnosed colorectal cancer survivors at any stage of disease from a prospective cohort study. Hematocrit and CRF (EORTC QLQ-C30) were assessed at diagnosis, six months, and two years after diagnosis. Multivariable logistic regression or multivariable linear mixed models were used to assess the associations of hematocrit with CRF prevalence, or CRF severity over time, respectively. Results: A low hematocrit (levels Conclusions: Lower hematocrit levels were longitudinally associated with a higher prevalence and severity of CRF in colorectal cancer. Impact: Our findings emphasize the importance of long-term anemia monitoring and a potential role of anemia in CRF among colorectal cancer survivors.

Year:

2024

Observational studies suggest that a healthy diet in combination with ample physical activity is associated with a lower prevalence of cancer-related fatigue. The SoFiT trial (SoFiT: Study on Fatigue: a lifestyle intervention among colorectal cancer survivors) will assess the effect of a personalised lifestyle programme on cancer-related fatigue in a randomised study. We designed a programme that aims to increase adherence to lifestyle recommendations on diet and physical activity. The programme was person-centred with regard to the lifestyle and personal characteristics of participants, to the determinants of behaviour of that participant, and to the preferences, opportunities and barriers of the participant. The effect of the programme was tested in the SoFiT trial: a two-armed, parallel, randomised controlled trial among adult stage I–III colorectal cancer survivors, who experience cancer-related fatigue after treatment completion; intended sample size n= 184. Participants randomised to the intervention group received the personalised lifestyle programme. During 6 months, participants in the intervention group had individual sessions with a lifestyle coach of which four sessions were face-to-face and eight sessions were remote. After 6 months, participants randomised to the control group had access to two lifestyle coaching sessions and to the same materials that the intervention group also received. The primary endpoint of the trial is cancer-related fatigue. Secondary endpoints are sleep quality and duration, health-related quality of life, physical performance, depression and anxiety, skeletal muscle echo intensity and cross-sectional area, and gut microbiota composition. This trial will show the effects of a personalised lifestyle programme on cancer-related fatigue and on an extensive set of secondary outcomes. Clinicaltrials.gov: NCT05390398.

Year:

2024

Collaborators (5)

Johannes H W de Wilt

Radboud University Medical Center

NETHERLANDS
View details

Fränzel J.B. van Duijnhoven

Wageningen University & Research

NETHERLANDS
View details

Bernardus Jacobus Maria Witteman

professor

Wageningen University & Research

NETHERLANDS
View details

Evertine Wesselink

Wageningen University & Research

NETHERLANDS
View details

Dieuwertje Kok

Wageningen University & Research

NETHERLANDS
View details